APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spinal and Bulbar Muscular Atrophy Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Spinal and Bulbar Muscular Atrophy Treatment Market Analysis and Forecast 2026-2032

19 December 2025198 pages

Choose your research edition.

Industry ResearchSpinal and Bulbar Muscular Atrophy Treatment Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Spinal and Bulbar Muscular Atrophy Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Spinal and Bulbar Muscular Atrophy Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spinal and Bulbar Muscular Atrophy Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Spinal and Bulbar Muscular Atrophy Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Spinal and Bulbar Muscular Atrophy Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Spinal and Bulbar Muscular Atrophy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Spinal and Bulbar Muscular Atrophy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Spinal and Bulbar Muscular Atrophy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Spinal and Bulbar Muscular Atrophy Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Spinal and Bulbar Muscular Atrophy Treatment include Sanofi, Johnson & Johnson, Pfizer, GlaxoSmithKline, AbbVie, Century Pharmaceuticals, Boehringer Ingelheim International and Astellas Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Spinal and Bulbar Muscular Atrophy Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Spinal and Bulbar Muscular Atrophy Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Spinal and Bulbar Muscular Atrophy Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Spinal and Bulbar Muscular Atrophy Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Spinal and Bulbar Muscular Atrophy Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Spinal and Bulbar Muscular Atrophy Treatment revenue, projected growth trends, production technology, application and end-user industry.

Spinal and Bulbar Muscular Atrophy Treatment Segment by Company

Sanofi

Johnson & Johnson

Pfizer

GlaxoSmithKline

AbbVie

Century Pharmaceuticals

Boehringer Ingelheim International

Astellas Pharma

Spinal and Bulbar Muscular Atrophy Treatment Segment by Type

5α-Reductase Inhibitors

Gonadotropin-releasing Hormone Agonists

Spinal and Bulbar Muscular Atrophy Treatment Segment by Application

Hospitals

Ambulatory Surgical Centers

Orthopedic Clinics

Spinal and Bulbar Muscular Atrophy Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spinal and Bulbar Muscular Atrophy Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spinal and Bulbar Muscular Atrophy Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spinal and Bulbar Muscular Atrophy Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Spinal and Bulbar Muscular Atrophy Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Spinal and Bulbar Muscular Atrophy Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Spinal and Bulbar Muscular Atrophy Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. 5α-Reductase Inhibitors Major Player Table 3. Gonadotropin-releasing Hormone Agonists Major Player Table 4. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Major Player Table 6. Ambulatory Surgical Centers Major Player Table 7. Orthopedic Clinics Major Player Table 8. Spinal and Bulbar Muscular Atrophy Treatment Industry Trends Table 9. Spinal and Bulbar Muscular Atrophy Treatment Industry Drivers Table 10. Spinal and Bulbar Muscular Atrophy Treatment Industry Opportunities and Challenges Table 11. Spinal and Bulbar Muscular Atrophy Treatment Industry Restraints Table 12. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2021-2026) Table 15. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2027-2032) Table 17. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Players (2021-2026) Table 19. Global Spinal and Bulbar Muscular Atrophy Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Spinal and Bulbar Muscular Atrophy Treatment Key Players Headquarters & Area Served Table 21. Global Spinal and Bulbar Muscular Atrophy Treatment Players, Product Type & Application Table 22. Global Spinal and Bulbar Muscular Atrophy Treatment Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Spinal and Bulbar Muscular Atrophy Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 39. Sanofi Recent Development Table 40. Johnson & Johnson Company Information Table 41. Johnson & Johnson Business Overview Table 42. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 44. Johnson & Johnson Recent Development Table 45. Pfizer Company Information Table 46. Pfizer Business Overview Table 47. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 49. Pfizer Recent Development Table 50. GlaxoSmithKline Company Information Table 51. GlaxoSmithKline Business Overview Table 52. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 54. GlaxoSmithKline Recent Development Table 55. AbbVie Company Information Table 56. AbbVie Business Overview Table 57. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 59. AbbVie Recent Development Table 60. Century Pharmaceuticals Company Information Table 61. Century Pharmaceuticals Business Overview Table 62. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 64. Century Pharmaceuticals Recent Development Table 65. Boehringer Ingelheim International Company Information Table 66. Boehringer Ingelheim International Business Overview Table 67. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 69. Boehringer Ingelheim International Recent Development Table 70. Astellas Pharma Company Information Table 71. Astellas Pharma Business Overview Table 72. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio Table 74. Astellas Pharma Recent Development Table 75. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 76. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 77. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 78. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 79. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (US$ Million) & (2027-2032) Table 82. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 83. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 84. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 85. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 86. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026) & (US$ Million) Table 88. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (US$ Million) & (2027-2032) Table 89. China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 90. China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 91. China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 92. China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 93. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 94. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 95. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 96. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Region (US$ Million) & (2021-2026) Table 99. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Region (US$ Million) & (2027-2032) Table 100. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026) & (US$ Million) Table 101. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032) & (US$ Million) Table 102. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026) & (US$ Million) Table 103. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032) & (US$ Million) Table 104. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026) & (US$ Million) Table 106. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (US$ Million) & (2027-2032) Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Spinal and Bulbar Muscular Atrophy Treatment Image Figure 2. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. 5α-Reductase Inhibitors Image Figure 5. Gonadotropin-releasing Hormone Agonists Image Figure 6. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Ambulatory Surgical Centers Image Figure 10. Orthopedic Clinics Image Figure 11. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size (US$ Million) & (2021-2032) Figure 12. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Spinal and Bulbar Muscular Atrophy Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2021-2032) Figure 19. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032) Figure 24. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032) Figure 25. North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Country (2021-2032) Figure 26. United States Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032) Figure 31. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032) Figure 32. Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Country (2021-2032) Figure 33. Germany Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032) Figure 43. China Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032) Figure 44. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032) Figure 46. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Region (2021-2032) Figure 48. Japan Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032) Figure 56. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032) Figure 57. SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Country (2021-2032) Figure 58. Brazil Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Spinal and Bulbar Muscular Atrophy Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 5α-Reductase Inhibitors
  • Gonadotropin-releasing Hormone Agonists
Applications
  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • GlaxoSmithKline
  • AbbVie
  • Century Pharmaceuticals
  • Boehringer Ingelheim International
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Spinal and Bulbar Muscular Atrophy Treatment Market by Type
  3. 1.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 5α-Reductase Inhibitors
  5. 1.2.3 Gonadotropin-releasing Hormone Agonists
  6. 1.3 Spinal and Bulbar Muscular Atrophy Treatment Market by Application
  7. 1.3.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Ambulatory Surgical Centers
  10. 1.3.4 Orthopedic Clinics
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Spinal and Bulbar Muscular Atrophy Treatment Market Dynamics
  1. 2.1 Spinal and Bulbar Muscular Atrophy Treatment Industry Trends
  2. 2.2 Spinal and Bulbar Muscular Atrophy Treatment Industry Drivers
  3. 2.3 Spinal and Bulbar Muscular Atrophy Treatment Industry Opportunities and Challenges
  4. 2.4 Spinal and Bulbar Muscular Atrophy Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Perspective (2021-2032)
  2. 3.2 Global Spinal and Bulbar Muscular Atrophy Treatment Growth Trends by Region
  3. 3.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Players
  2. 4.1.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Spinal and Bulbar Muscular Atrophy Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Spinal and Bulbar Muscular Atrophy Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Spinal and Bulbar Muscular Atrophy Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Spinal and Bulbar Muscular Atrophy Treatment Players, Product Type & Application
  8. 4.5 Global Spinal and Bulbar Muscular Atrophy Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market CR5 and HHI
  11. 4.6.3 2025 Spinal and Bulbar Muscular Atrophy Treatment Tier 1, Tier 2, and Tier 3
5 Spinal and Bulbar Muscular Atrophy Treatment Market Size by Type
  1. 5.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2021-2032)
6 Spinal and Bulbar Muscular Atrophy Treatment Market Size by Application
  1. 6.1 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 AbbVie
  26. 7.5.1 AbbVie Company Information
  27. 7.5.2 AbbVie Business Overview
  28. 7.5.3 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  30. 7.5.5 AbbVie Recent Developments
  31. 7.6 Century Pharmaceuticals
  32. 7.6.1 Century Pharmaceuticals Company Information
  33. 7.6.2 Century Pharmaceuticals Business Overview
  34. 7.6.3 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  36. 7.6.5 Century Pharmaceuticals Recent Developments
  37. 7.7 Boehringer Ingelheim International
  38. 7.7.1 Boehringer Ingelheim International Company Information
  39. 7.7.2 Boehringer Ingelheim International Business Overview
  40. 7.7.3 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  42. 7.7.5 Boehringer Ingelheim International Recent Developments
  43. 7.8 Astellas Pharma
  44. 7.8.1 Astellas Pharma Company Information
  45. 7.8.2 Astellas Pharma Business Overview
  46. 7.8.3 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product Portfolio
  48. 7.8.5 Astellas Pharma Recent Developments
8 North America
  1. 8.1 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue (2021-2032)
  2. 8.2 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country
  11. 8.6.1 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue (2021-2032)
  2. 9.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country
  11. 9.6.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Spinal and Bulbar Muscular Atrophy Treatment Revenue (2021-2032)
  2. 10.2 China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032)
  5. 10.3 China Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032)
  9. 10.5 China Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue (2021-2032)
  2. 11.2 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country
  11. 11.6.1 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country
  11. 12.6.1 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Spinal and Bulbar Muscular Atrophy Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst